acetylcysteine oral / Generic mfg. - LARVOL DELTA

Randomized, placebo-controlled trial of N-acetylcysteine in Parkinson's disease patients: a pilot study. (PubMed, Metab Brain Dis) - "This pilot trial evaluated the one-year tolerability of oral N-acetylcysteine (NAC) 1200 mg/day in Parkinson's disease (PD) and explored associations with clinical progression, levodopa dose, and striatal dopamine-transporter imaging. Completer laboratories were unremarkable, but safety cannot be established from completers alone. These data do not establish disease modification and require confirmation in a larger, prospectively powered trial."

Clinical • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Clinical efficacy, safety evaluation, and mechanism of acetylcysteine in improving first-line anti-tuberculosis treatment of newly diagnosed pulmonary TB: an open-label, randomized, single-center trial. (PubMed, Front Med (Lausanne)) - "The Control group received standard HRZE therapy, whereas the Aerosol NAC and Oral NAC groups received additional nebulized N-acetylcysteine (300 mg twice daily) or oral N-acetylcysteine (600 mg once daily), respectively. The incidence of adverse reactions was lower in both NAC groups (10.0%) than in the Control group (40.0%) (p < 0.05). Adjunctive N-acetylcysteine, administered either by aerosol inhalation or orally, significantly improved treatment outcomes, accelerated sputum conversion, reduced oxidative stress and inflammation, protected liver function, and decreased adverse events in patients with newly diagnosed pulmonary tuberculosis."

Journal • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IFNG • IL4

Cystinuria: Diagnosis, Medical and Surgical Management, and Emerging Therapies. A Narrative Review. (PubMed, Res Rep Urol) - "Oral N-acetylcysteine has mechanistic plausibility and a favorable, well-characterized safety profile in other clinical settings, making it a rational candidate for formal prospective evaluation; however, robust clinical trial evidence in cystinuria using contemporary monitoring parameters is lacking. Current standard treatment remains insufficient for a substantial proportion of patients, underscoring the need to evaluate accessible adjunctive therapies with defined mechanisms and measurable outcomes."

Journal • Review • Chronic Kidney Disease • Nephrology • Renal Calculi • Renal Disease

Investigating the effectiveness of N-acetyl cysteine mouthwash in preventing chemotherapy-induced oral mucositis: a randomized, double-blind controlled trial. (PubMed, BMC Oral Health) - "According to the findings, NAC mouthwash lessens mucositis severity and may help to prevent its onset."

Clinical • Journal • Mucositis • Preventive care • Stomatitis

Successful survival after severe aluminum phosphide poisoning complicated by cardiogenic shock, atrial fibrillation and severe metabolic acidosis: a case report. (PubMed, J Med Case Rep) - "With prompt and effective supportive care, survival in severe cases of ALP poisoning can be achieved. Rapid hemodynamic stabilization, correction of metabolic derangements, and antioxidant therapy can help to improve the outcome. The case highlights the need to recognize it as soon as possible, closely monitor it, and implement preventive strategies to decrease ALP-associated fatalities."

Journal • Atrial Fibrillation • Cardiovascular • CNS Disorders • Depression • Hypotension • Major Depressive Disorder • Metabolic Disorders • Mood Disorders • Psychiatry

A Case of Onychotillomania Triggered by Underlying Inflammatory Nail Disorder (BAD 2026) - "Methotrexate first addressed the primary inflammatory driver of the itch, followed by oral N-acetylcysteine to target the neuropsychiatric component of onychotillomania, as described in the literature. Persistent nail dystrophy despite treatment, especially in patients with significant psychological distress, should prompt evaluation for onychotillomania, and dermoscopy can be a helpful tool for diagnosis. Clinicians should be alerted to this comorbidity in refractory cases, notwithstanding the small number of cases reported thus far."

Clinical • CNS Disorders • Contact Dermatitis • Dermatitis • Immunology • Inflammation • Mood Disorders • Pruritus • Psoriasis

Therapeutic effect of N-acetylcysteine in severe or critical coronavirus disease 2019 pneumonia: A retrospective cohort study. (PubMed, J Int Med Res) - "After 1:1 propensity score matching, 176 patients were divided into two groups based on whether oral N-acetylcysteine was administered for at least 3 days. Given the retrospective design and potential residual confounding, these findings should be interpreted as exploratory.ConclusionsIn this retrospective cohort study, treatment with N-acetylcysteine for at least 3 days was associated with a possible reduction in mortality or disease progression during hospitalization in patients with severe or critical coronavirus disease 2019 pneumonia. Prospective studies are needed to confirm these observations."

Journal • Retrospective data • Critical care • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

ACOX1 Gain-of-Function and De Novo ROBO1 Variant in ACOX1-sEDD. (PubMed, Pediatr Dermatol) - "Metabolic testing showed elevated dicarboxylic acids and medium-/long-chain acylcarnitines despite normal very-long-chain fatty acids and classical peroxisomal biomarkers, and trio exome sequencing identified de novo ACOX1 c.710A>G (p.Asn237Ser) and ROBO1 c.572delG (p.Cys191fs) variants. Cutaneous disease resolved with topical 10% N-acetylcysteine and emollients, in conjunction with oral N-acetylcysteine and adjunctive antioxidant vitamin therapy, while ocular involvement improved with vitamin A ointment and autologous serum eyedrops, supporting early recognition of ACOX1-sEDD in infants with inflammatory ichthyosiform dermatitis and ocular-neurologic involvement and suggesting that additional neurodevelopmental variants may modify disease expression."

Journal • CNS Disorders • Dermatitis • Dermatology • Epilepsy • Immunology • ACOX1

ORAL N-ACETYLCYSTEINE FOR MENSTRUAL PAIN IN ADOLESCENTS: A RANDOMIZED CONTROLLED STUDY OF OXIDATIVE STRESS REDUCTION WITHOUT HORMONAL MODULATION. (PubMed, Georgian Med News) - "Oral NAC during menstruation reduced the intensity of pain, biomarkers of oxidative stress, and NSAID use in adolescents with primary dysmenorrhea significantly. Such results make NAC a safe, non-hormonal, and mechanistically plausible intervention. Further research is required to prove long-term benefit and to directly compare NAC to other antioxidant interventions."

Clinical • Journal • Pain • Women's Health

High-dose N-acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial. (PubMed, Mult Scler) - P2 | "To assess whether oxidative stress drives biomarkers implicated in disability progression independent of relapses, we randomized 2:1 fifteen adults with progressive MS (Expanded Disability Status Scale (EDSS): 2.0-6.5) to receive high-dose oral N-acetyl cysteine (NAC, 1250 mg TID), a major source of endogenous antioxidants, or placebo for 4 weeks (NCT02804594)...NAC resulted in decreased glial fibrillary acidic protein (median change: -10.1 pg/mL vs. 39.5 pg/mL, p = 0.008) alongside stable neurofilament light chain levels (median change: 0.25 pg/mL vs. 0.61 pg/mL, p = 0.777). Our exploratory biomarker findings suggest NAC may be a promising agent to delay MS progression."

Journal • CNS Disorders • Multiple Sclerosis • GFAP • NEFL

Severe Dengue-Associated Hepatitis in an Adolescent Treated With Oral Acetylcysteine: A Case Report. (PubMed, Cureus) - "Oral N-acetylcysteine (NAC) was initiated as adjuvant therapy. This case describes the use of NAC as an adjuvant therapy in severe dengue-associated hepatitis. Further studies are required to evaluate its potential role in this setting."

Journal • Dengue Fever • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Liver Failure • Pediatrics • Thrombocytopenia

Role of N-Acetylcysteine in Treating Solar Purpura (EADV-Sp 2026) - "Materials and Methods Based on preliminary observations, discussions with colleagues, and use in other dermatologic indications, we decided to use N-Acetylcysteine, an oral supplement available over the counter, previously prescribed as a mucolytic for lung diseases in a dose of 600 mg BID as an intervention. Our data suggest that long-term N-Acetylcysteine supplementation may represent a safe, practical adjunct in managing chronic solar purpura. Further controlled studies are needed to clarify mechanisms of action at the molecular level and establish treatment guidelines."

Gastroenterology • Gastrointestinal Disorder • Pulmonary Disease • Respiratory Diseases

Idiopathic Intracranial Hypertension Associated With Therapeutic-Dose N-Acetylcysteine in a 6-Year-Old Boy: A Case Report. (PubMed, J Child Neurol) - "We report a case of PTCS temporally associated with standard-dose oral N-acetylcysteine (NAC)...Acetazolamide and topiramate were started with no improvement; symptoms and papilledema improved rapidly within 24 hours of NAC discontinuation...Clinicians should consider medication-induced PTCS in children who present with new-onset headaches and papilledema. Further pharmacovigilance and reporting are warranted."

Journal • Cardiovascular • CNS Disorders • Hypertension • Oncology • Pain • Pediatrics

Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (clinicaltrials.gov) - P1/2 | N=46 | Completed | Sponsor: Tanta University | Recruiting ➔ Completed

Trial completion • Pancreatitis

NAC Attack: Oral N-acetylcysteine for Retinitis Pigmentosa (clinicaltrials.gov) - P3 | N=485 | Active, not recruiting | Sponsor: Johns Hopkins University | Trial completion date: May 2029 ➔ May 2030

Trial completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (clinicaltrials.gov) - P2/3 | N=180 | Completed | Sponsor: Ain Shams University | Recruiting ➔ Completed

Trial completion

Neuroprotective effects of plasma-activated N-acetylcysteine against streptozotocin-induced behavioral deficits in rats: Attenuation of oxidative stress and cholinergic dysfunction. (PubMed, Ecotoxicol Environ Saf) - "At the transcriptional level, PAN upregulated α7 nAChR, Nrf2 and BDNF expression while downregulating AChE and Keap1. Collectively, these findings suggest that PAN mitigates behavioral impairments in the icv-STZ rat model of Alzheimer's disease, potentially through attenuation of oxidative stress and restoration of cholinergic neurotransmission."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Mood Disorders • Pain • Psychiatry • ACHE • BDNF • KEAP1

Overlapping Hepatic and Neurological Toxicity Following Intentional Multidrug Poisoning with Acetaminophen, Metoclopramide, and Metronidazole: A Case Report. (PubMed, Clin Med Insights Case Rep) - "Management included oral N-acetylcysteine for APAP toxicity, intravenous diphenhydramine and diazepam for extrapyramidal symptoms, supportive ICU care, and psychiatric intervention. Rapid identification and agent-specific management, including NAC for APAP, symptomatic therapy for metoclopramide and metronidazole toxicity, and supportive care, resulted in full recovery without long-term sequelae. Emergency clinicians should maintain high suspicion for multiple co-ingestants and use targeted interventions to optimize outcomes."

Journal • Ataxia • Hematological Disorders • Movement Disorders • Psychiatry

Effects of topically applied liquid N-acetylcysteine for the management of burning mouth syndrome. (PubMed, Sci Rep) - "Topically administered liquid NAC demonstrates potential as an effective and well-tolerated therapeutic strategy for managing BMS, offering symptom relief with minimal systemic burden. Although the combination with clonazepam did not demonstrate sustained superiority at 8 weeks, its principal advantage is a faster onset of improvement in OHIP‑14 K, evident by week 4."

Clinical • Journal • Neuralgia • Pain

Protocol for NAC Attack, a phase-3, multicenter randomized, parallel, double masked, placebo controlled trial evaluating the efficacy and safety of oral N-acetylcysteine (NAC) in patients with retinitis pigmentosa. (PubMed, medRxiv) - P3 | "Therefore, the trial is of high public health, clinical, and scientific significances. The ClinicalTrials.gov ID for NAC Attack is NCT05537220 ."

Clinical • Journal • P3 data • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Inhaled Relief: Rethinking Mucolytics with Nebulized N-Acetylcysteine (APSR 2025) - "Post-antibiotic treatment, while his systemic symptoms resolved, he continued to experience significant respiratory distress due to thick tracheostomy secretions despite treatment with nebulized 0.9% and 3% saline and oral N- acetylcysteine (NAC). Nebulized NAC may be considered a valuable adjunct in palliative or supportive care settings to improve airway clearance and patient comfort. Further studies are needed to establish standardized protocols and assess broader efficacy."

Acute Kidney Injury • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Hematological Malignancies • Hypertension • Infectious Disease • Lymphoma • Metabolic Disorders • Nephrology • Palliative care • Peripheral T-cell Lymphoma • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • T Cell Non-Hodgkin Lymphoma

Glutathione deficiency and disturbances of sulfur homeostasis in the pathophysiology of schizophrenia (PubMed, Postepy Biochem) - "In one of the recently developed rat’s neurodevelopmental model, schizophrenic-like changes were induced by administration of buthioninesulfoximine (BSO) - an inhibitor of glutathione synthesis and a dopamine reuptake inhibitor - the compound GBR 12909 during the developmental period...The usefulness of the developed model was tested by the effect of the antipsychotic drug aripiprazole and N-acetylcysteine...At the biochemical level, both drugs significantly reduced the elevated concentration of bound sulfane sulfur in the hippocampus of model rats. Recent studies indicate that in the neurodevelopmental pathophysiology of schizophrenia, disturbances in the homeostasis of sulfur compounds play an important role, which are corrected by the action of drugs."

Journal • Review • CNS Disorders • Psychiatry • Schizophrenia

The Effectiveness and Safety of Oral N-Acetylcysteine in Combination With Narrow-Band Ultraviolet B (NB-UVB) Phototherapy Compared With NB-UVB Phototherapy Alone in the Treatment of Vitiligo: A Pilot Study. (PubMed, Health Sci Rep) - "Oral NAC appears to be a safe adjuvant therapy in the treatment of generalized vitiligo patients in combination with NB-UVB phototherapy. "Evaluation of the efficacy of NB-UVB phototherapy with oral N- acetylcysteine compared with NB-UVB phototherapy alone in the treatment of vitiligo patients: a randomized controlled clinical trial".Clinical trial registration number: IRCT20210729052013N1."

Clinical • Journal • Dermatology • Immunology • Vitiligo

Oral N-Acetylcysteine in Hepatitis C-Induced Acute Liver Injury: A Case Report (ACG 2025) - "This case highlights a patient with chronic liver diseases of HCV and non-alcoholic fatty liver disease (NAFLD) who was started on oral NAC in the setting of non-acetaminophen liver failure.Case Description/ A 54-year-old male with a past medical history of HCV (previously treated/sustained virological response), NAFLD, and recent cocaine/methamphetamine use presented with cough and markedly elevated transaminases (AST 778, ALT 1069). Oral NAC may benefit select patients with HCV and acute liver injury, particularly when IV formulations are unavailable or contraindicated. Further studies are needed to define optimal dosing, timing, and patient selection."

Case report • Clinical • Cough • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Failure • Metabolic Dysfunction-Associated Steatotic Liver Disease • Respiratory Diseases

Rescue with Redox: An Underutilized Therapeutic Attempt in Antitubercular Therapy-Induced Liver Injury (ACG 2025) - "We present the first adult case demonstrating rapid biochemical reversal of severe AT-DILI using intravenous glutathione(GSH) after oral N-acetylcysteine (NAC) failure, averting liver transplantation.Case Description/ A 35-year-old male with active pulmonary tuberculosis developed jaundice, pruritus, and coagulopathy with an International Normalized Ratio(INR) of 7.55 and a Model for End-Stage Liver Disease(MELD) score of 34 one month after initiating the first-line antitubercular therapy. Aldini G et al. Free Radic Res 2018; 52(7):751–62"

Dermatology • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Pruritus • Respiratory Diseases • Tuberculosis